NicOx S.A. | Mutual Funds
Mutual Funds that own NicOx S.A.
HBM BioVentures Ltd.
1,713,313
5.79%
153,313
1.05%
12/31/2017
Arbarin, SICAV
288,202
0.97%
80,031
1.14%
03/31/2018
Royance Sélection Internationale
283,380
0.96%
0
11.53%
05/31/2018
APO Medical Opportunities
224,826
0.76%
129,816
0.38%
03/31/2018
FCP OP Medical BioHe@lth-Trends
180,631
0.61%
53,000
0.93%
11/30/2017
DFA Continental Small Company Series
136,752
0.46%
0
0.02%
01/31/2018
APO Medical Opportunities Institutionell
99,133
0.34%
0
0.45%
06/29/2018
86,259
0.28%
0
0.16%
06/30/2018
Apus Capital Revalue Fonds
75,000
0.25%
17,500
0.37%
09/30/2017
Amilton Small Caps
44,737
0.15%
44,737
0.41%
06/30/2017
| Address |
Drakkar 2 - Bât D
Sophia-Antipolis Provence-Alpes-Cote-dAzur 06560
France
|
|
Employees
|
- |
| Website |
http://www.nicox.com |
| Updated |
07/08/2019 |
| Nicox SA is an ophthalmology company, which engages in developing innovative solutions to help maintain vision and improve ocular health. Its products include Zerviate, and Vyzulta. The company was founded by Piero Del Soldato, Michele Garufi and Elizabeth Marie Robinson on February 15, 1996 and is headquartered in Sophia-Antipolis, France. |
